Epoprostenol sodium and Bronchitis - a phase IV clinical study of FDA data

Summary:

Bronchitis is found among people who take Epoprostenol sodium, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Epoprostenol sodium and have Bronchitis. It is created by eHealthMe based on reports of 2,337 people who have side effects when taking Epoprostenol sodium from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 18, 2023

2,337 people reported to have side effects when taking Epoprostenol sodium.
Among them, 7 people (0.3%) have Bronchitis.

What is Epoprostenol sodium?

Epoprostenol sodium has active ingredients of epoprostenol sodium. eHealthMe is studying from 2,340 Epoprostenol sodium users for its effectiveness, alternative drugs and more.

What is Bronchitis?

Bronchitis (inflammation of the mucous membrane in the bronchial tubes) is found to be associated with 3,007 drugs and 2,394 conditions by eHealthMe.

Number of Epoprostenol sodium and Bronchitis reports submitted per year:

Could Epoprostenol sodium cause Bronchitis?

Gender of people who have Bronchitis when taking Epoprostenol sodium *:

female: 100 %
male: 0.0 %

Age of people who have Bronchitis when taking Epoprostenol sodium *:

Common drugs people take besides Epoprostenol sodium *:

Common side effects people have besides Bronchitis *:

Weakness: 1 person, 14.29%
Urinary Tract Infection: 1 person, 14.29%
Upper Respiratory Tract Infection: 1 person, 14.29%
Pneumonia: 1 person, 14.29%
Liver Function Test Abnormal: 1 person, 14.29%
Joint Swelling: 1 person, 14.29%
Injection Site Pain: 1 person, 14.29%
Gamma-Glutamyltransferase Increased: 1 person, 14.29%
Drug Ineffective: 1 person, 14.29%
Dermatitis Exfoliative (widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss): 1 person, 14.29%

Common conditions people have *:

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 7 people, 100.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Epoprostenol sodium and have Bronchitis?

Check whether Bronchitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Common Epoprostenol sodium side effects:

Browse all side effects of Epoprostenol sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Bronchitis treatments and more:

Bronchitis (104,445 reports)

COVID vaccines that are related to Bronchitis:

Common drugs associated with Bronchitis:

All the drugs that are associated with Bronchitis:

Bronchitis (3,008 drugs)

Common conditions associated with Bronchitis:

All the conditions that are associated with Bronchitis:

Bronchitis (2,394 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on epoprostenol sodium (the active ingredients of Epoprostenol sodium) and Epoprostenol sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.